再生元制药(REGN.US)Inmazeb成为美国FDA批准的首个用于治疗埃博拉感染的药物
© Reuters. 再生元制药(REGN.US)Inmazeb成为美国FDA批准的首个用于治疗埃博拉感染的药物
智通财经APP获悉，再生元制药(REGN.US)宣布，其埃博拉治疗药物Inmazeb已获美国FDA批准。
Inmazeb是一种研究性三抗体鸡尾酒疗法(atoltivimab、maftivimab和odesivimab-ebgn)，是首个被批准用于治疗成人和儿童埃博拉感染的药物。
目前，Inmazeb已获得“孤儿药”认定，FDA也授予了它“突破性疗法”的认定。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
If you like, reward to support.
Hot
No comment on record. Start new comment.